Skip to main content Skip to footer

Algernon Pharmaceuticals Inc.

  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Pipeline
    • Overview
    • NP-120 (Ifenprodil)
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Dec 05, 2019 6:00am EST

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

Nov 25, 2019 7:00am EST

Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial

Aug 02, 2019 7:00am EDT

Algernon Pharmaceuticals Announces Emoxypine (NP-178), a Top Selling Drug in Russia, as its Lead Drug for Inflammatory Bowel Disease

Jul 31, 2019 7:00am EDT

Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies

Jul 29, 2019 7:00am EDT

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%

Jul 03, 2019 7:00am EDT

Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone

Apr 04, 2019 7:00am EDT

Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board

Apr 01, 2019 7:00am EDT

Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study

Mar 21, 2019 7:00am EDT

Algernon Pharmaceuticals Appoints Leading Liver Disease Expert Dr. Arun Sanyal to Its Medical and Scientific Advisory Board

Mar 12, 2019 11:46pm EDT

Algernon Retains Renmark Financial Communications

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap